Drug Search Results
More Filters [+]

Procarbazine

Alternative Names: procarbazine, natulan, matulane
Latest Update: 2024-06-27
Latest Update Note: Clinical Trial Update

Product Description

Procarbazine is an orally administered alkylating agent used in combination with other antineoplastic agents in the therapy of Hodgkin’s disease and malignant melanoma. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Procarbazine)

Mechanisms of Action: Protein Synthesis Inhibitor,DNA Synthesis Inhibitor,RNA Synthesis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Canada | Chile | France | Germany | Greece | Hong Kong | India | Ireland | Italy | Japan | Lithuania | Malta | New Zealand | Pakistan | Peru | Portugal | Romania | Russia | Slovenia | Spain | Switzerland | Taiwan | Thailand | Ukraine | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: Radiation Therapy Oncology Group
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Procarbazine

Countries in Clinic: Kenya, Spain, Zimbabwe

Active Clinical Trial Count: 5

Highest Development Phases

Phase 3: Glioma|Hodgkin Lymphoma

Phase 2: AIDS-Related Lymphoma|B-Cell Leukemia|Diffuse Large B-Cell Lymphoma|Large-Cell Immunoblastic Lymphoma|Leukemia, Plasma Cell|Lymphoid Leukemia|Lymphoma, Non-Hodgkin|Plasmablastic Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Primary Central Nervous System Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2018-005027-16

P3

Active, not recruiting

Glioma

2030-09-14

HD21 (advanced stage)

P3

Active, not recruiting

Hodgkin Lymphoma

2025-10-18

FIORELLA Trial

P2

Active, not recruiting

Primary Central Nervous System Lymphoma

2025-05-01

BrEPEM-LH-22017

P2

Active, not recruiting

Hodgkin Lymphoma

2023-10-30

Recent News Events